GlassScriptPhysician profile
Louis Laluna
NPI 1073580486
$8,309.91
in general payments reported to CMS, 2019-2025
39 companies · $183 in 2025
The $183 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,532 · 2020: $729 · 2021: $1,628 · 2022: $1,542 · 2023: $1,612 · 2024: $1,084 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,771 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,771.13 |
| Education | $108.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,826.23 | 2019-2024 | |
| Celgene Corporation | $811.65 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $740.84 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $694.05 | 2019-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $624.82 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $571.00 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $504.58 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $284.14 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $215.47 | 2019-2023 | Ocaliva |
| Mallinckrodt Hospital Products INC. | $189.19 | 2022-2024 | Terlivaz |
| Boston Scientific Corporation | $183.18 | 2020-2021 | |
| Genzyme Corporation | $173.57 | 2022-2024 | |
| Qol Medical, LLC | $162.13 | 2019-2024 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $119.20 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $111.33 | 2020-2023 | Rebyota |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $107.37 | 2025 | Fibroscan |
| Ironwood Pharmaceuticals, INC | $104.95 | 2020-2023 | Linzess |
| Janssen Scientific Affairs, LLC | $94.48 | 2019 | |
| Shionogi INC | $82.41 | 2019 | |
| Redhill Biopharma INC. | $81.55 | 2020-2021 | |
| Allergan, INC. | $66.18 | 2019 | |
| Daiichi Sankyo INC. | $59.17 | 2019-2024 | Injectafer |
| Biofire Diagnostics, LLC | $58.97 | 2019 | |
| Phathom Pharmaceuticals, INC. | $48.11 | 2024 | Voquezna |
| Lilly USA, LLC | $42.28 | 2024 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $41.00 | 2024 | Iqirvo, Bylvay |
| Merck Sharp & Dohme LLC | $39.27 | 2022-2024 | Dificid, Zerbaxa, Zinplava |
| Ucb, INC. | $38.56 | 2019-2020 | |
| Braintree Laboratories, INC. | $34.76 | 2022 | |
| Endo Pharmaceuticals INC. | $33.46 | 2019 | |
| Madrigal Pharmaceuticals | $29.58 | 2024 | Resmetirom |
| Sandoz INC. | $24.78 | 2024 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $24.61 | 2023 | |
| Celltrion USA INC. | $18.51 | 2024 | Zymfentra |
| Fresenius Kabi USA, LLC | $18.21 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $17.83 | 2023 | Zeposia |
| Ardelyx, INC. | $17.05 | 2023 | Ibsrela |
| Medtronic, INC. | $15.44 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Laluna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.